APR 16, 2018 10:49 PM PDT

Senators Put Fire to Jeff Sessions to Fulfill Policy Change on Expanding Supply to Medical Marijuana Research

WRITTEN BY: Melissa Moore

On April 12, 2018 Bipartisan senators Orrin Hatch (R-Utah) and Kamala Harris (D-Calif.) sent a letter to the Department of Justice (DOJ) and US Attorney General Jeff Sessions in an effort to encourage the Drug Enforcement Administration (DEA) to fulfill its promise on allowing for more manufacturers to supply research-grade marijuana. Almost two years ago the DEA changed its policy which allowed for more suppliers in regard to medical marijuana research. Although 25 manufacturers have applied, none have been approved, and the only manufacturer-the University of Mississippi- holds a license to produce marijuana for federally sanctioned research. As of August 11, 2016, there was 354 individuals and institutions approved by the DEA to conduct research on marijuana and its related components. The supply needed for research is clearly not meeting the demand. Hatch and Harris point out that research will give law enforcement guidance, and veterans (amongst other patients) "deserve scientifically-based assessments of the substance many of them are already self-administering". The letter ends requesting that by May 15, 2018 the DEA to provide notice of the date the DOJ expects to complete its review of the applications by, and to give notice to the applicants of the timeline for resolution and the status of their applications. It also asks for a commitment to resolve applications by August 11, 2018. To drive their message home, Hatch and Harris remind Sessions that he stated before the Judiciary Committee on October 18, 2017 "that competition among federally-approved marijuana providers would be healthy".

 

Sources: Hatch Senate, TheHill, youtube

 

About the Author
  • Currently working with Pharmacannis, a dispensary in Buffalo, NY. Resided in Northern California for the past 15 years working in the cannabis industry as a farmer, breeder, and chemical analyst. Received a bachelor's degree in biology at Keuka College in NY. Studied nursing at Mendocino College in CA, and currently attending University at Buffalo for a Master's of Education in Science and the Public. I have a passion for research with a focus in the field of endocannabinology.
You May Also Like
JUL 21, 2020
Health & Medicine
FDA Produces Draft Guidelines on Developing Cannabis Drugs
JUL 21, 2020
FDA Produces Draft Guidelines on Developing Cannabis Drugs
The FDA’s Center for Drug Evaluation and Research has produced guidelines for research into cannabis-related ingre ...
JUL 22, 2020
Immunology
CBD May Reduce Cytokine Storm & Lung Inflammation in COVID-19
JUL 22, 2020
CBD May Reduce Cytokine Storm & Lung Inflammation in COVID-19
Initial studies of cannabidiol’s impact of classic symptoms of lung damage in severe cases of COVID-19 provide a p ...
JUL 29, 2020
Cannabis Sciences
CBD Tablets Help People Quit Cannabis
JUL 29, 2020
CBD Tablets Help People Quit Cannabis
Cannabis use disorder is essentially cannabis addiction. Although research suggests that it affects 9% of peop ...
AUG 05, 2020
Cannabis Sciences
Cannabis Might Trigger Heart Problems Says AHA
AUG 05, 2020
Cannabis Might Trigger Heart Problems Says AHA
The American Heart Association (AHA) has produced a new statement about medical marijuana and recreational cannabis. The ...
AUG 25, 2020
Cannabis Sciences
Synthetic Cannabinoid Drug to Enter Human Trials
AUG 25, 2020
Synthetic Cannabinoid Drug to Enter Human Trials
In recent months, interest has been growing in the potential for cannabinoids- the compounds found in cannabis- to treat ...
AUG 25, 2020
Cannabis Sciences
FDA Approves Cannabis Drug to Treat Rare Genetic Disease
AUG 25, 2020
FDA Approves Cannabis Drug to Treat Rare Genetic Disease
The US Food and Drug Administration has approved Epidiolex, a cannabidiol (CBD) oral solution, to treat seizures linked ...
Loading Comments...